Abstract |
The Trial of Preventing Hypertension (TROPHY) demonstrated the feasibility of possibly reducing the incidence of hypertension with the angiotensin receptor blocker candesartan compared with placebo. The long-term benefits of pharmacologic therapy in high-normal blood pressure, or prehypertension are not known, and the long-term effect on health-related quality of life (HRQL) has not been determined. An analysis of covariance model was used to assess treatment differences from baseline in the HRQL scores using Short Form (SF)-36, and component measures at subsequent visits. Of the 809 randomized patients, 734 had both baseline and > or =1 HRQL follow-up assessment: 95% (379 of 397) of patients receiving candesartan and 91% (355 of 388) of patients receiving placebo. There were no statistically significant between-group differences in least-squares mean physical component survey and mental component survey scores or the individual scales at each scheduled visit relative to baseline values (P >.05). In TROPHY, patients with prehypertension had relatively high baseline HRQL, and HRQL was maintained with the angiotensin receptor blocker candesartan over both the 2-year treatment period and a total 4-year trial period.
|
Authors | Setareh A Williams, Eric L Michelson, Valerie A Cain, Min Yang, Shawna D Nesbitt, Brent M Egan, Stevo Julius, TROPHY Study Investigators |
Journal | Journal of clinical hypertension (Greenwich, Conn.)
(J Clin Hypertens (Greenwich))
Vol. 10
Issue 6
Pg. 436-42
(Jun 2008)
ISSN: 1524-6175 [Print] United States |
PMID | 18550933
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Benzimidazoles
- Biphenyl Compounds
- Placebos
- Tetrazoles
- candesartan
|
Topics |
- Adult
- Aged
- Angiotensin II Type 1 Receptor Blockers
(therapeutic use)
- Benzimidazoles
(therapeutic use)
- Biphenyl Compounds
- Double-Blind Method
- Female
- Humans
- Hypertension
(epidemiology, prevention & control)
- Incidence
- Male
- Middle Aged
- Placebos
- Quality of Life
- Surveys and Questionnaires
- Tetrazoles
(therapeutic use)
- Treatment Outcome
- United States
(epidemiology)
|